AX Versus AC as Adjuvant Treatment for Node-Negative Breast Cancer
Capecitabine has shown high efficacy in metastatic and adjuvant settings. This is a prospective, randomised trial, to compare the efficacy and safety profiles of capecitabine-containing regimen with non- capecitabine-containing adjuvant chemotherapy regimens for node negative breast cancer patients.
Breast Cancer
DRUG: Doxorubicin, Cyclophosphamide|DRUG: doxorubicin, Capecitabine
disease-free survival, 5 years
Overall survival, 5 years|Adverse event rate (CTCAE v. 3.0), 3 years and 5 years
Capecitabine has shown high efficacy in metastatic and adjuvant settings. This is a prospective, randomised trial, to compare the efficacy and safety profiles of capecitabine-containing regimen with non- capecitabine-containing adjuvant chemotherapy regimens for node negative breast cancer patients.